ARWR — Arrowhead Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.67bn
- $2.24bn
- $240.74m
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 68 | -84.6 | -141 | -176 | -209 |
Depreciation | |||||
Non-Cash Items | 13.5 | 43.9 | 76.9 | 128 | 94.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 87.2 | -60.7 | 227 | -98.3 | -51.5 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 173 | -95.4 | 171 | -136 | -154 |
Capital Expenditures | -12 | -12 | -23.6 | -52.8 | -177 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -35.7 | -229 | -118 | 47.4 | 80.6 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -47.7 | -241 | -142 | -5.42 | -96.2 |
Financing Cash Flow Items | 0 | 0 | — | 60 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 66.4 | 258 | 11.3 | 65.2 | 253 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 192 | -78.2 | 40.9 | -76.4 | 2.89 |